Agios Q3 Revenue Reaches $55.4M as Sickle Cell PDUFA Slips to February 2027
AGIO sits 43% above its 52-week low of $22.24.
Summary
Third-quarter product revenue at Agios reached $55.4 million, more than four times last year, while the FDA pushed the mitapivat sickle cell decision to February 1, 2027 after requesting REMS information. Cash of $907.0 million funds the launches, with non-GAAP profitability targeted for 2028.
Key Events · Earnings and Guidance · AGIO
-
Q3 Product Revenue Quadruples
Worldwide mitapivat net revenue was $55.4 million versus $12.9 million a year earlier, split $48.7 million U.S. and $6.6 million ex-U.S.; U.S. revenue rose 20% sequentially on the AQVESME thalassemia launch.
-
Sickle Cell PDUFA Delayed to February 2027
The FDA moved the mitapivat sickle cell sNDA goal date from November 1, 2026 to February 1, 2027 after requesting information on whether a REMS is needed and classifying the response as a major amendment; labeling discussions continue.
-
Loss Narrows on Cost Cuts
Net loss was $65.0 million, or $1.09 per share, versus $103.4 million a year ago; R&D expense fell to $73.5 million from $86.8 million as headcount was cut by over 100 roles, a more than 35% reduction versus 2025.
-
Cash Funds Launches Through 2028 Target
Cash, cash equivalents and marketable securities totaled $907.0 million at September 30, 2026, down from $1.2 billion at December 31, 2025, which management says funds both commercial launches and the pipeline with non-GAAP profitability targeted for 2028.
Analysis · AGIO · Life Sciences
The bull case rests on product revenue more than quadrupling to $55.4 million, with the company saying it has already topped its entire 2025 total in nine months. Against that, the sickle cell launch — mitapivat's largest addressable market — is now three months later than planned, after the FDA asked for more information on whether a REMS is needed and treated the reply as a major amendment. A $907.0 million balance sheet still funds both launches without raising money, and management is pointing to non-GAAP profitability in 2028. Helped by R&D cuts of more than 100 roles, the quarter's loss narrowed to $65.0 million from $103.4 million a year ago.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AGIO was trading at $31.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $22.24 to $46.00. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.